Great Point Partners’s Nektar Therapeutics NKTR Stock Holding History

Great Point Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2M	Sell	175,000 -141,453	-45%	-$10.4M	2.31%	19
2026 Q1	$22.8M	Buy	316,453 +105,721	+50%	+$6.02M	5.23%	6
2025 Q4	$8.91M	Sell	210,732 -89,268	-30%	-$5M	2.89%	15
2025 Q3	$17.1M	Buy	+300,000	New	+$9.93M	7.04%	3
2022 Q4	–	Sell	-29,855	Closed	-$1.43M	–	50
2022 Q3	$1.43M	Sell	29,855 -180,145	-86%	-$10.7M	0.35%	37
2022 Q2	$12M	Buy	+210,000	New	+$13.2M	2.87%	15
2021 Q4	–	Sell	-33,646	Closed	-$7.3M	–	43
2021 Q3	$9.06M	Buy	+33,646	New	+$8.09M	2.11%	21
2019 Q4	–	Sell	-141,667	Closed	-$38.7M	–	43
2019 Q3	$38.7M	Buy	+141,667	New	+$52M	3.56%	11

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Point Partners's NKTR Position: Q2 2026 in Review

Great Point Partners reduced its Nektar Therapeutics (NKTR) stake by 45% in Q2 2026, selling an estimated $10.4M and leaving 175,000 shares worth $12.2M. The position accounts for 2.31% of the portfolio, ranked #19.

Great Point Partners first reported a position in NKTR in Q3 2019 and has held it in 8 quarters since. The position peaked at $38.7M in Q3 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Great Point Partners held 175,000 shares of Nektar Therapeutics worth $12.2M as of Q2 2026.
Great Point Partners sold 141,453 Nektar Therapeutics shares in Q2 2026, an estimated $10.4M.
Nektar Therapeutics made up 2.31% of Great Point Partners's portfolio in Q2 2026, its #19 holding.
Great Point Partners first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 8 quarters since.
Great Point Partners's Nektar Therapeutics position peaked at $38.7M in Q3 2019.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.